Document Detail


Antineoplastic agents 460. Synthesis of combretastatin A-2 prodrugs.
MedLine Citation:
PMID:  12049477     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The original synthesis of combretastatin A-2 (1a) was modified to provide an efficient scale-up procedure for obtaining this antineoplastic stilbene. Subsequent conversion to a useful prodrug was accomplished by phosphorylation employing in situ formation of dibenzylchlorophosphite followed by cleavage of the benzyl ester protective groups with bromotrimethylsilane to afford the phosphoric acid intermediate 11. The latter was immediately treated with sodium methoxide to complete a practical route to the disodium phosphate prodrug (2a). The phosphoric acid precursor (11) of phosphate 2a was employed in a parallel series of reactions to produce a selection of metal and ammonium cation prodrug candidates. Each of the phosphate salts (2a-q) was evaluated with respect to relative solubility behavior, cancer cell growth inhibition and antimicrobial activity.
Authors:
G R Pettit; B R Moser; M R Boyd; J M Schmidt; R K Pettit; J C Chapuis
Related Documents :
9282507 - In vitro antiviral activity of indigenous glycyrrhizin, licorice and glycyrrhizic acid ...
18959927 - Photometric determination of niobium with azo-dyestuffs.
9708267 - Inhibition of aspergillus niger and aspergillus flavus by some herbs and spices.
23528177 - Fatty acid-regulated transcription factors in the liver.
5004197 - Appearance of a methylated ribonucleic acid on illumination of euglena gracillis cells ...
747817 - Isolation and partial characterization of the parasporal body of bacillus popilliae.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Anti-cancer drug design     Volume:  16     ISSN:  0266-9536     ISO Abbreviation:  Anticancer Drug Des.     Publication Date:    2001 Aug-Oct
Date Detail:
Created Date:  2002-06-06     Completed Date:  2002-06-19     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8603523     Medline TA:  Anticancer Drug Des     Country:  United States    
Other Details:
Languages:  eng     Pagination:  185-93     Citation Subset:  IM    
Affiliation:
Cancer Research Institute and Department of Chemistry and Biochemistry, Arizona State University, Tempe 85287-2404, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Phytogenic / chemical synthesis*,  chemistry,  pharmacology
Bacteria / drug effects
Bibenzyls / chemical synthesis*,  chemistry,  pharmacology
Drug Design
Humans
Indicator Dilution Techniques
Indicators and Reagents
Isomerism
Microbial Sensitivity Tests
Neoplasms / metabolism
Phosphates / chemical synthesis,  chemistry
Prodrugs / chemical synthesis*,  chemistry,  pharmacology
Solubility
Stilbenes*
Tumor Cells, Cultured
Grant Support
ID/Acronym/Agency:
CA44344-05-12/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Bibenzyls; 0/Indicators and Reagents; 0/Phosphates; 0/Prodrugs; 0/Stilbenes; 82855-09-2/combretastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Review: DNA molecular electrostatic potential: novel perspectives for the mechanism of action of ant...
Next Document:  The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.